Navigation Links
3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
Date:9/25/2008

data which demonstrates that an once a week injection of 36,000 IU high-dose EPIAO is as effective as the three times per week 10,000 IU low-dose EPIAO in treating cancer patients with chemotherapy-induced anemia. If approved, high-dose EPIAO will provide patients and physicians in China with a new, safe and more convenient treatment of anemia resulting from chemotherapy. Furthermore, we believe that the greater convenience provided by high-dose EPIAO treatment versus existing treatment options will be a key factor in helping to fuel the growth of the highly under-penetrated oncology market in China."

About the Phase III Data

The Phase III study was a multi-center, randomized, active-controlled trial that enrolled 206 non-myeloid malignant tumor patients. The testing group, including 104 patients, was given 36,000 IU EPIAO subcutaneously once a week for eight weeks. The control group, including 102 patients, was given 10,000 IU EPIAO three times a week for eight weeks. The primary endpoint of the study was the improvement of the Hemoglobin level for > 1-2 g/dL compared to the baseline level. The trial result shows that 70% of patients on high- dose EPIAO injections had Hemoglobin improvement of at least 1-2 g/dL from baseline level, similar to those receiving three times per week dosing of 10,000 IU EPIAO. In addition, the patients were assessed with the peak Hemoglobin value, the nadir of Hemoglobin value, the time it took for the Hemoglobin level to increase for more than 1g/dL and 2g/dL, and the need for blood transfusion for each group. There was no significant difference between the two groups in these secondary endpoints.

In addition, the safety of high-dose EPIAO was comparable to the 10,000 IU EPIAO. The most common adverse effect related to high-dose EPIAO was low fever. The patients recovered within a short period of time.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researc
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and SUMMERLAND, British Columbia , ... XON ), a leader in synthetic biology, ... acquire  Okanagan Specialty Fruits (OSF), the pioneering agricultural ... the world,s first non-browning apple. Through the acquisition, Intrexon ... that is more appetizing and convenient for consumers while ...
(Date:2/27/2015)... February 27, 2015 The fully ... (Nexera UC) can sequentially analyze up to 48 ... with high-sensitivity detection of targets by mass spectrometry. ... to fulfill the measurement requirements of a wide ... products, drug delivery and search for disease biomarkers, ...
(Date:2/27/2015)... , Feb. 27, 2015  Steep Hill, the ... US and internationally, intends to open a full service ... New Mexico , bringing advanced scientific tools and ... Steep Hill is currently the only laboratory ... conduct potency and contaminant testing in order to meet ...
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the fiscal first quarter ... release are in Canadian dollars (CAD), unless otherwise stated. ... to win new business from our existing customers and ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... September 3 Debiopharm Group, SA,(Debiopharm), a Swiss-based ... the development of prescription drugs that target unmet ... to Dr Lluis,Quintana-Murci from the Institut Pasteur in ... field of evolutionary genetics of,infection. Funded by Debiopharm, ...
... Ontario, Sept. 3 Helix BioPharma Corp. (TSX, FSE: "HBP" ... chief operating officer, will present at the Rodman and Renshaw ... Sept. 9, at the New York Palace Hotel in New ... Company,s leading product development programs L-DOS47 and Topical Interferon Alpha-2b. ...
... Sept. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... China, announced today that,the State Food and Drug Administration ... vaccine, and has issued Sinovac a,production license for this ... which showed that PANFLU.1, Sinovac,s H1N1,vaccine, has a good ...
Cached Biology Technology:The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 2The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 3Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 3Sinovac Obtains Production License for H1N1 Vaccine 2Sinovac Obtains Production License for H1N1 Vaccine 3
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
(Date:2/5/2015)... --NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces the launch ... part of its 2015 marketing and branding initiatives for ... consumer website for Wocketwallet.com earlier this month. ... "Our new corporate website naturally showcases our premiere consumer ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... Australian parents need to be educated about managing fever ... often unnecessarily, according to a Queensland University of Technology ... conducted the first study into how Australian parents, manage ... results were published in the latest Journal of Paediatrics ...
... 5 bioMETRX, Inc. (OTC,Bulletin Board: BMRX) a ... that it has acquired a patent that covers ... locks. The company believes that this patent ... years, consumers have been using portable locks, such ...
... of a science fiction thriller, researchers at UC Davis have ... of jaws located in the moray,s throat reaches forward into ... the esophagus for swallowing. "This is really an amazing ... Mehta, a postdoctoral researcher in the Section of Evolution and ...
Cached Biology News:Fever causing headaches for Aussie parents 2bioMETRX, Inc. Acquires Patent for Biometric Padlock 2'Alien' jaws help moray eels feed 2
Canine Chondrocytes (CnC) (500,000 cells)...
... Hex, Tet Cy3, Cy5, Texas Red, ... Hole Quenchers Molecular Beacons* ... 3 Dabcyl Dabcyl*Licensed from the ... labelled probes are purified either by HPLC ...
... Varioskan is a high performance ... dispenser and incubator. With the advanced ... and reliability for drug discovery assay ... for fluorescence intensity, time-resolved fluorescence and ...
Roll of Mesh 5m x 25cm...
Biology Products: